Neurontin: Clinical Trials

4 trials of Neurontin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 recruiting. 4 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Completed 3, Recruiting 1
Phase 21Recruiting 1

Follow Neurontin: new trials by email Literature Review of Neurontin trials Research Report on Neurontin

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
Gabapentin, Ketamine - Head and Neck Cancer, Locally Advanced Head and Neck Carcinoma
Phase 1 / Phase 2RecruitingNatalie Lockney642022-01-242024-10-21
Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation
Gabapentin, Methadone Hydrochloride, Oxycodone Hydrochloride - Head and Neck Squamous Cell Carcinoma, Pain
Phase 1CompletedRoswell Park Cancer Institute602015-04-242022-07-25
Maintenance Gabapentin to Prolong Pregnancy.
Gabapentin - Preterm Labor, Premature Birth
Phase 1CompletedState University of New York at Buffalo42013-06-012023-02-14
Drug Discrimination in Methadone-Maintained Humans Study 1
Cycloserine, Diltiazem, Gabapentin - Drug Dependence
Phase 1CompletedUniversity of Arkansas402006-09-012011-03-11

Conditions studied

Head and Neck Neoplasms (1)  ·  Obstetric Labor, Premature (1)  ·  Opioid-Related Disorders (1)  ·  Pain (1)  ·  Premature Birth (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Stomatitis (1)  ·  Substance-Related Disorders (1)

Sponsors

Natalie Lockney (1)  ·  Roswell Park Cancer Institute (1)  ·  State University of New York at Buffalo (1)  ·  University of Arkansas (1)

Countries

United States (4)

Top investigators

Alison Oliveto, PhD (1)  ·  Anurag Singh (1)  ·  Natalie Lockney, MD (1)

NIH funding

R01DA010017 (1)